Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03515551 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
A Phase 1 study, sponsored by Immunocore.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03515551 is a Phase 1 study that was terminated before completion, run by Immunocore. The registered enrollment target is 29 participants.
The verdict
NCT03515551, a Phase 1 study, was terminated before completion, sponsored by Immunocore.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
IMCnyeso is a bispecific fusion protein designed for the treatment of cancers that express NY-ESO-1 and/or LAGE-1A. This was a first-in-human trial designed to evaluate the safety and efficacy of IMCnyeso in HLA-A\*02:01-positive adult participants whose cancer is positive for NY-ESO-1 and/or LAGE-A1.
Interventions
- DRUG IMCnyeso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2021-05-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03515551
The ClinicalTrials.gov registry entry for NCT03515551 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunocore, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMCnyeso is the first listed.
NCT03515551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03515551 about?
NCT03515551 is a clinical study titled "Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers". IMCnyeso is a bispecific fusion protein designed for the treatment of cancers that express NY-ESO-1 and/or LAGE-1A. This was a first-in-human trial designed to evaluate the safety and efficacy of IMCnyeso in HLA-A\*02:01-positive adult participants whose cancer is positive for NY-ESO-1 and/or LAGE-A...
What is the current status of trial NCT03515551?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2018-06-15. Estimated completion is 2021-05-10.
What interventions are being tested in trial NCT03515551?
The interventions under investigation include: IMCnyeso (DRUG).
Who is sponsoring clinical trial NCT03515551?
This trial is sponsored by Immunocore, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.